Welcome to our dedicated page for Galecto SEC filings (Ticker: GLTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Galecto Inc., whose recent SEC reports identify the registrant as Damora Therapeutics, Inc. following Galecto's acquisition of privately held Damora Therapeutics in November 2025, files disclosures covering biotechnology corporate structure, governance, and equity compensation. Form 8-K reports document executive officer appointments and departures, related compensation arrangements, and changes in the registrant's independent registered public accounting firm.
Proxy materials describe board matters, executive compensation, equity-award information, pay-versus-performance data, shareholder voting items, and governance procedures. The filing record also reflects public-company reporting around Galecto/Damora corporate status and clinical-stage therapeutic development.
Galecto, Inc. (GLTO) – Form 4 insider filing
On 18 June 2025, non-employee director Dallas Jayson Donald Alexander received an automatic grant of 720 stock options under the company’s Director Compensation Policy. The options carry an exercise price of $3.22 per share, a 10-year term expiring 18 June 2035, and will vest in equal monthly installments over one year. The filing lists the director’s ownership as direct and discloses no sales or other equity transactions.
Given the small size of the grant and its routine nature, the disclosure is unlikely to have a material impact on Galecto’s valuation or trading dynamics; however, it does incrementally align director incentives with shareholder value through equity-based compensation.
Galecto (NASDAQ: GLTO) submitted a routine Form 4 detailing a small insider equity grant.
On 18 June 2025, director Amit Munshi received a stock option for 720 common shares at an exercise price of $3.22 per share. The grant was issued under the company’s Non-Employee Director Compensation Policy in conjunction with the 2025 Annual Meeting. The option vests in equal monthly installments over one year and expires on 18 June 2035. Following the transaction, Munshi beneficially owns 720 derivative securities; no non-derivative share holdings were reported.
The filing is administrative in nature, disclosing routine director compensation with no material impact on Galecto’s financial position or governance profile.
Galecto (NASDAQ:GLTO) filed a routine Form 4 reporting that director David Shapiro received a stock option for 720 common shares at an exercise price of $3.22 on June 18, 2025. The award was granted under the company’s Non-Employee Director Compensation Policy and will vest in equal monthly installments until the first anniversary of the grant date. No shares were sold or otherwise disposed of, and Shapiro now directly holds 720 derivative securities following the reported transaction.
Galecto (NASDAQ:GLTO) filed a routine Form 4 disclosing that director Anne Prener received an automatic equity award under the company’s Non-Employee Director Compensation Policy.
On 18 June 2025, Prener was granted 720 non-qualified stock options with an exercise price of $3.22 per share. The options vest in equal monthly instalments over 12 months and expire on 18 June 2035. No common shares were sold or otherwise disposed of, and her beneficial ownership now reflects the 720 newly issued options. The filing contains no other transactions, sales, or material amendments.